reSee.it - Related Video Feed

Big Food is secretly trying to hack Ozempic with the help of a food laboratory called Matson, run by Justin Shimick. Matson is reformulating ingredients to bypass the effects of GLP-1 weight loss drugs because these drugs are cutting into food company profits. Walmart's CEO has noticed that people on these medications are buying less food. Food companies are designing "GLP-1 optimized products" to make food even more addictive by using tactics like nostalgic aromas, amplified artificial sweeteners, and altered salt crystals. This is all being done in secret as Justin Shimick wouldn't disclose which companies he's working with, stating that they are "professional secret keepers". The end result could be that obesity persists, drugs with side effects become ineffective, and it's all shrouded in secrecy.

Drug companies won't test natural substances because they can't be patented. FDA requires testing for safety and efficacy, but natural products won't be tested due to lack of patentability. This creates a cycle where natural remedies are deemed unproven by the FDA.

Ozempic, containing semaglutide, became a household name due to its weight loss effects, though it belongs to a class of drugs used for decades to treat type 2 diabetes. While diabetes treatments haven't gained similar recognition despite the high mortality rate, Ozempic's weight loss effects on celebrities propelled it into the spotlight. Clinical trials indicated that these drugs are the most effective weight loss drugs ever. Semaglutide mimics the GLP-1 hormone. Semaglutide is found in both Ozempic and Wegovy, but Wegovy is FDA approved for weight loss.

The speaker expresses shock upon learning that GLP-1 drugs like Wegovy and Ozempic are derived from lizard venom. They question whether people believe their weight and diabetes are due to a Gila monster venom deficiency, requiring them to inject venom weekly. The speaker is skeptical of the drugs' safety and effectiveness despite FDA approval, citing concerns about stomach paralysis and thyroid cancer risks. They claim to have educated the world about this venom-based drug after learning about it and being invited on shows to discuss it.

Novo Nordisk has faced accusations of shady sales tactics, including spending heavily on doctors, and has encountered regulatory issues in multiple countries. The company, along with other drug makers, has been criticized for high insulin prices. While insulin profits have decreased, weight loss drugs offer astronomical profit potential, which Novo Nordisk is already capitalizing on. The company's valuation once exceeded Denmark's entire GDP. Some individuals, distrustful of big pharma or lacking access to these drugs, are seeking alternatives.

Over 100 members of Congress are backing a bill to fund Ozempic through Medicare at $1,500 monthly, many having received funds from Novo Nordisk, its European manufacturer. Once Medicare approves it, Medicaid follows. There's a push to prescribe Ozempic to kids as young as six for obesity, a largely preventable condition. With 74% of Americans obese, covering everyone's Ozempic would cost $3 trillion annually. Ozempic has made Novo Nordisk Europe's largest company, yet Denmark recommends diet and exercise instead. The company's value relies heavily on projected Ozempic sales in the US. For half the cost, we could provide organic food and gym memberships for every obese American. Why are politicians siding with a Danish company over American farmers and kids? Because Novo Nordisk heavily funds medical research, influencing media, politicians, and medical schools.

Dr. Josef Duhring and Dr. Yosef (Doctor Yosef Duhring) discuss antidepressants and SSRIs, outlining perceived risks, data limitations, and long-term concerns, followed by practical guidance on tapering and contact information for a tapering clinic. Key side effects and risks cited - Common side effects: gastrointestinal issues (nausea, vomiting, diarrhea), changes in sleep (insomnia or drowsiness), headaches, nervousness, restlessness, dry mouth, sweating, tremors, sexual dysfunction, decreased libido, difficulty reaching orgasm, erectile dysfunction, appetite and weight changes (gain or loss). - Other reported effects: emotional blunting, feeling less like yourself, dizziness, balance issues (especially early in treatment), increased sweating, abnormal dreams. - Serious but rarer risks: suicidal thoughts or behaviors, particularly under age 25; serotonin syndrome (described as rare); heart rhythm changes at high doses with some SSRIs. - Behavioral effects: mania, psychosis, irritability, aggression; rare but potentially misdiagnosed as bipolar disorder; in some cases leading to escalation to lithium or antipsychotics. - Sleep and long-term effects: SSRI use diminishing sleep quality (less REM and deep sleep), resulting in fatigue and brain fog in long-term users. - Long-term data gaps: “there has never been a randomized control study that looked at them for over a year,” and “seventy percent of antidepressant users are on these drugs for two years or more.” Claims that there is no long-term data on sustained efficacy or safety beyond eight to twelve weeks. Efficacy and data concerns - Most drugs reach market based on eight-week studies; there is a reported two-point difference on a 52-point depression scale between the drug and placebo, which is described as clinically very low. - Outcomes most meaningful to patients (employment, relationships, life meaning) are not directly measured in standard trials, which focus on scale-based movement. - The claim is made that long-term efficacy remains unproven and that the long-term data are unavailable. Observations about prescription patterns and systemic factors - Online “pill mill” platforms allegedly enable easy access to SSRIs (Lexapro), sometimes without video chats, via online questionnaires, with rapid mail delivery. - The dose of prescription and patient interactions are affected by time constraints and economic incentives in healthcare delivery, leading to faster checklists and medication-based treatments rather than in-depth discussions of life context, relationships, or non-drug approaches. - An “unholy alliance” between the pharmaceutical industry and academic medicine is described: investigators may pursue drug trials for career advancement and publications funded by drug companies, potentially biasing conclusions in favor of medications. - The FDA’s stance is portrayed as influenced by this environment, with concerns about regulatory capture and inadequate critical evaluation of risks, including suicide risk data and withdrawal issues. Key long-term and withdrawal considerations - Long-term withdrawal: physicians are described as telling patients that antidepressant withdrawal is mild and resolves in two weeks, but tapering often requires one to two years to avoid withdrawal symptoms; many are tapered too quickly, leading to relapse or withdrawal challenges. - Tapers and recovery: the clinician reports patients improving emotionally during tapering, sometimes even before complete discontinuation; success depends on broader life health improvements (physical health, relationships, purpose) and careful, gradual reduction. Three major concerns observed with antidepressants (as described by Dr. Yosef) - They don’t work for many patients in the long term; diminished efficacy over time due to emotional blunting and neurochemical adaptation. - Behavioral and cognitive changes: potential for mania, psychosis, irritability, and misdiagnosis as bipolar disorder; risk of “drug-induced” psychiatric symptoms. - Toxicity and sleep: long-term blunting reduces emotional responsiveness; chronic sleep disruption and brain fog; long-term toxicity may underlie persistent symptoms after prolonged use. Clinical implications and guidance offered - For those considering antidepressants, emotions matter and should be explored beyond a chemical-imbalance narrative; discuss physical health, relationships, purpose, substances, and non-drug approaches (therapy, lifestyle changes) before relying on medication. - For those already on SSRIs, a careful, patient-guided taper is advised: slowly reduce dosages, use approaches such as liquid tapering to control precise reductions, and listen to one’s body to avoid withdrawal; a two-year taper may be necessary for many patients. - Coming off antidepressants can reveal or restore aspects of life and personality; benefits may appear during tapering as engagement and motivation return, but life circumstances must be addressed in parallel to avoid relapse. Contact information - Tapering clinic website: taperclinic.com (for patients in the U.S.; clinic claims to operate in about 15–16 states, covering roughly 70% of the population). - YouTube channel for further resources: Doctor Yosef (German version) with a free drug tapering training (about five hours) and guidance for working with a doctor. Speaker names - Dr. Yosef Duhring (referred to as Doctor Josef Duhring in the discussion) and Dr. Yosef (the same speaker) are cited; their experiences include FDA and industry roles and a tapering clinic specializing in antidepressant withdrawal and discontinuation.

Drug companies are not interested in natural substances that cannot be patented. The FDA requires substances to be tested for safety and effectiveness before they can be used legally. However, since natural substances cannot be patented, drug companies are unlikely to spend the money to test them. As a result, the FDA will always consider natural substances unproven and condemn them.

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Speaker 0 argues that history will view this presidency as probably the most reckless and corrupt in the history of the United States, and expresses fear that without change the country and the world risk major harm, including the possibility of World War III. They say, regardless of views on global leadership, that being on top “what good is it … if you've created an absolute hellscape?” They emphasize the need for the course to change and suggest the future of the United States as a cohesive country and the world is currently in question because of the administration’s behavior. Speaker 1 agrees that America used to hold the moral high ground—defending human rights, free speech, and free trade—but asserts that none of those things are true any longer. They claim America is “the terror regime of the world,” describing it as pillaging, stealing, bombing, assassinating, running color revolutions, lying, and doing everything possible to destroy others to keep America as the last nation standing on its pile of soon to be worthless debt. They state this is not a moral position from which to lead any civilization. Speaker 0 contends that America has the tools to be all those values, citing a great constitutional republican system, the federation of states, resources, and human capital. They note a problem, however: a “giant pile of worthless fiat paper,” with the bill coming due and the tantrums of an empire, referencing warnings by people like Gerald Celente and Alex Jones about a fiat bubble rupture. They say the question is where the country wants to be in the world, criticizing a lack of imagination among the “great and the good in America” about a compelling future. Speaker 1 adds a new issue: 31 million Americans are injecting themselves with GLP-1 drugs, which they say cause a 100% increase in risk of psychiatric disorders and suicidal ideation, especially among women, with the most use among 50–65-year-olds. They claim Trump is working to make these drugs more affordable so that more people can take them, potentially leading to half of US adults using a drug based on venom peptides of the Gila monster, a paralyzing agent, risking madness. They compare this to lead poisoning and reference Ozempic as one of these drugs. Speaker 0 asks, “What’s it called? Ozempic? Is that a GOP one?” Speaker 1 confirms “Ozempic,” and notes that the drugs are used for vanity to look healthy, not because people are actually healthy. They reiterate the core issue: what goes into bodies and the environment in which people live, stressing that there is an opportunity today to correct and improve the situation, and that many are taking that opportunity.

Ozempic breaks people's bones. Pharmaceutical companies selling weight loss pills have side effects that include breaking people's bones. Instead of cleaning up their diet, eating organic, working out, getting rid of Wi Fi, and spending time in nature, people are going to pharmaceutical companies expecting results. When your bones break in half, it doesn't matter if you lose weight. Taking care of yourself and being healthy takes work. If you're concerned about weight loss, you should be concerned about what's in your house, what you're eating, the chemicals you're spraying all over your body, and the lotions you're putting all over your head. If you can't lose weight, it's probably your diet, and an all-organic diet can heal everything. Pharmaceutical companies poison people to gain weight, then sell them something to make them lose weight, which causes their bones to break, creating patients for life.

Ozempic carries a black box warning for increasing the risk of all forms of medullary thyroid cancer within twelve months of use. Oncologists are seeing new cancer patients on Ozempic and Wegovy developing breast cancer in under a year. Thousands of Americans are reporting eye-rotting diseases from using Ozempic and Wegovy. Ozempic and Wegovy are made from protein from the Gila monster lizard. According to the Smithsonian Institute, Gila monster venom is more deadly and toxic than a western diamondback rattlesnake. The speaker asks if people taking Ozempic and Wegovy believe they are overweight, diabetic, or have heart disease due to a Gila monster venom deficiency.

Ozempic, containing semaglutide, has become popular for weight loss, overshadowing its original purpose: regulating blood sugar in type 2 diabetes. Semaglutide is a GLP-1 receptor agonist, mimicking a naturally occurring hormone. Clinical trials for obesity, not diabetes, have propelled Ozempic to household name status due to its weight loss effects. These trials suggest semaglutide-based drugs are the most effective weight loss drugs ever. Semaglutide is found in both Ozempic and Wegovy, but Wegovy is specifically FDA-approved for weight loss.

Pharmaceutical companies are allegedly commissioning "ghost articles" from writing companies that mimic legitimate medical journal articles. These articles, complete with graphs, charts, numbers, and references, are written without named authors. Pharmaceutical companies then approach well-known oncologists, offering them authorship in exchange for having their names listed on the article, which will then be published in prestigious journals like the New England Journal of Medicine. These journals influence how doctors treat patients. Doctors, unaware of the article's ghostwritten nature, may prescribe the drug based on the article's claims of tremendous responses and minimal complications, relaying this information to patients. Thus, doctors and patients are allegedly being deceived because the article is not independent.

Ozempic has rapidly become a cultural phenomenon, with one in eight US adults having tried GLP-1 drugs. The company producing Ozempic is now valued higher than Coca-Cola and McDonald's combined. Online discussions mention side effects like Ozempic face, hair loss, and severe stomach problems, alongside reports suggesting potential benefits for fertility, Alzheimer's, and even shopping addiction. The speaker questions the complete truth about GLP-1 drugs and weight loss, and has spent months researching and attempting to obtain GLP-1 medication.

The speaker addresses misinformation circulating on social media regarding a certain medication. A recurring claim is that these drugs are new, not well-studied, and not well-understood. Another speaker specifies that there are no studies on what the medication does to a body without diabetes, and no research on a person not diagnosed with type two diabetes. The first speaker refutes the claim that they are untested or not understood, stating that they have been studied a lot for both safety and efficacy for diabetes.

A few years ago, the New York Attorney General discovered that 79% of supplements from Target, GNC, Walmart, and Walgreens did not contain the ingredients they claimed to have. Some even contained sawdust instead. Only 4% of Walmart products tested had DNA from the listed plants. To ensure you're getting quality supplements, it's important to buy from companies that conduct third-party testing and have high-quality facilities. The speaker, who has experience in pharmaceutical sales, recommends trusting certain brands that do their own due diligence.

Natural substances cannot be patented, which means drug companies are not interested in testing them for FDA approval. The FDA requires substances to be tested for safety and efficacy before they can be used legally. However, since natural substances cannot be patented, no one is willing to spend the money to conduct these tests. As a result, the FDA will always consider natural substances unproven and condemn them.

Ozempic carries a black box warning that it increases the risk of all forms of medullary thyroid cancer within twelve months of use. Oncologists are seeing new cancer patients on Ozempic and Wegovy developing breast cancer in under a year. People magazine reported thousands of Americans are experiencing eye-rotting diseases while using Ozempic and Wegovy. Ozempic and Wegovy are made from protein from the Gila monster lizard. The Smithsonian Institute told CNN that Gila monster venom is more deadly and toxic than a western diamondback rattlesnake. The speaker asks if people taking Ozempic and Wegovy believe they are overweight, diabetic, or have heart disease because they are Gila monster venom deficient.

The average 65-year-old in the US takes about seven drugs. 95% of people on the USDA nutrition guidelines had conflicts of interest with food companies, influencing school lunches, where the USDA serves 3 billion meals yearly. Kraft Heinz is brokering deals to put Lunchables in schools, a top growth area. Novo Nordisk, the Ozempic manufacturer, is now Europe's most valuable company, with almost all revenue from the US due to a broken system. 30% of Americans with insurance coverage stop using Ozempic within three months, despite it being touted as a lifetime drug. Lawsuits are emerging regarding gastrointestinal issues and stomach paralysis, which may persist after discontinuing the drug. The EU is probing suicidal ideation linked to Ozempic. The American Academy of Pediatrics recommends Ozempic as a first-line defense for teens based on a 68-week study. Pharma is the largest TV news ad spender, and Novo Nordisk is a major funder of obesity research, medical groups, and civil rights groups, including paying the NAACP, who claims that not supporting Ozempic is racist. Analyst reports assume increased obesity rates, and loans for obesity treatment centers project growth in obesity. Weight Watchers, now an Ozempic prescriber, shifted from personal accountability due to Ozempic's superior business model.

Americans are programmed to trust only FDA-approved drugs, but Big Pharma buys the FDA's approval. The FDA stopped independently reviewing all drugs about 30 years ago. Drugmakers can pay a lump sum upfront, such as $10,000,000, to get immediate approval to sell their products. The approval is granted if the drugmaker believes and can prove through their own research studies that the drug is safe and effective.